Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTEROID: ASTX660 and Pembrolizumab in Advanced Solid Tumours
NCT05082259Phase 1Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolinapant in solid tumor, Cervical Cancer (CC), triple negative breast cancer (TNBC) and 2 more (2 arms), sponsored by The Institute of Cancer Research. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 12 months, Safety and tolerability at 12 months and 1 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
tolinapant
03
Conditions
solid tumorCervical Cancer (CC)triple negative breast cancer (TNBC)glioblastoma (GBM)estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT05082259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082259.